Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02400320
Recruitment Status : Withdrawn
First Posted : March 27, 2015
Last Update Posted : September 12, 2017
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
The purpose of this study is to determine local skin safety of a topical analgesic spray containing a combination of diclofenac, methyl salicylate, menthol and compare it with a topical analgesic gel containing a combination of diclofenac, methyl salicylate, and menthol.

Condition or disease Intervention/treatment Phase
Skin Irritation Drug: Topical Spray Drug: Topical Gel Other: Saline Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Other
Official Title: Cumulative Skin Irritation Study Evaluating the Skin Irritancy Potential of Topical Analgesic Vovilup Spray Containing a Combination of Diclofenac, Menthol, Methyl Salicylate and Linseed Oil and Comparing it With a Marketed Formulation - Iodex Ultragel
Estimated Study Start Date : March 1, 2016
Estimated Primary Completion Date : June 1, 2016
Estimated Study Completion Date : June 30, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Topical Spray
Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
Drug: Topical Spray
Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.

Experimental: Topical Gel
Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
Drug: Topical Gel
Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%

Saline
Saline
Other: Saline
Saline




Primary Outcome Measures :
  1. Mean cumulative irritation score [ Time Frame: 7 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

  1. Healthy male or female volunteers aged at least 18 years.
  2. Good general, physical and mental health in the opinion of the investigator or medically qualified designee:

    • No clinically significant and relevant abnormalities in medical history or upon physical examination.
    • Absence of any condition that could affect the volunteer's safety or well being or their ability to understand and follow study procedures and requirements.
  3. Healthy volunteers who do not have excessive hair on the volar aspect of the forearm(s).
  4. Healthy volunteers should understand and be willing to fully comply with all study procedures and restrictions.
  5. Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
  6. Females of childbearing potential, using an effective contraceptive method for at least one month before the beginning of the study, and willing to use throughout the study

Exclusion Criteria

  1. Volunteers having recent history (within one year) of alcohol or other substance abuse as determined by medical history.
  2. Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.
  3. Previous participation in similar study with similar products.
  4. Volunteer has any visible skin disease at the site of application that, in the opinion of the investigator, will interfere with the skin assessments.
  5. Volunteer has current or relevant previous history of serious, severe or unstable physical or psychiatric illness, or medical disorders, such as current or previous history of hepatic or renal diseases (impairment) or peptic ulcer as determined by medical history.
  6. Volunteer has a history of hypersensitivity (e.g. asthma, bronchospasm, rhinitis, urticaria, nasal polyps) to aspirin, diclofenac, other non steroidal anti-inflammatory drugs (NSAIDs), menthol or any of the excipients in the test product(s).
  7. Volunteer is receiving systemic or topical NSAIDs, other oral or topical analgesics or antihistamine within 3 days of visit 1, or other medication (such as corticosteroids within 3 weeks of visit 1) which, in the opinion of the investigative personnel, will interfere with the study results.
  8. Female volunteers who are pregnant, planning to become pregnant during the study, or are breast-feeding.
  9. Female volunteers who have positive pregnancy test.
  10. Volunteers who are employees of the sponsor or study site or an immediate family member (e.g. partner, offspring, parents, siblings or sibling's offspring) of such employees.
  11. Any skin disorder at the test site that in the investigator's judgement can affect the readings of the test result
  12. Any concomitant medications that in the investigator's judgement can confound or alter test results or evaluation of adverse events.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02400320


Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline

Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT02400320     History of Changes
Other Study ID Numbers: 202201
First Posted: March 27, 2015    Key Record Dates
Last Update Posted: September 12, 2017
Last Verified: September 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Salicylic Acid
Diclofenac
Salicylates
Methyl salicylate
Menthol
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antipruritics
Dermatologic Agents
Anti-Infective Agents
Antifungal Agents
Keratolytic Agents